All In Biotech

Drug Trial Radar · NCT07930507

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients

A Phase III, Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Dec 21, 2026

Primary completion

Oct 11, 2027

Study completion Oct 11, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients with hypercholesterolaemia. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.

Conditions

  • Hypercholesterolemia

Interventions

  • LaroprovstatDrug

    daily oral dose of the Laroprovstat

  • Rosuvastatin 1Drug

    daily oral dose of the Rosuvastatin 1

  • Rosuvastatin 2Drug

    daily oral dose of the Rosuvastatin 2

  • FDC laroprovstat/Rosuvastatin 1Drug

    daily oral dose of the FDC Laroprovstat/Rosuvastatin 1

  • FDC laroprovstat/Rosuvastatin 2Drug

    daily oral dose of the FDC Laroprovstat/Rosuvastatin 2

  • Placebo to match rosuvastatinDrug

    daily oral dose of the Placebo to match Rosuvastatin

  • Placebo to match laroprovstat or FDC laroprovstat/rosuvastatinDrug

    daily oral dose of the Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in LDL-CTime frame: Week 8
  2. Relative change in LDL-CTime frame: Week 8

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Chifeng, China

  • Research Site

    Guangzhou, China

  • Research Site

    Ha’erbin, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Liuzhou, China

  • Research Site

    Luoyang, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Sanya, China

  • Research Site

    Shanghai, China

  • Research Site

    Shantou, China

  • Research Site

    Shiyan, China

  • Research Site

    Suining, China

  • Research Site

    Tangshan, China

  • Research Site

    Tianjin, China

  • Research Site

    Yueyang, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Zigong, China

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Ampang, Malaysia

  • Research Site

    Beseri, Malaysia

  • Research Site

    Kuala Kedah, Malaysia

  • Research Site

    Puchong, Malaysia

  • Research Site

    Sarawak Miri, Malaysia

  • Research Site

    Daegu, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Wŏnju, South Korea

  • Research Site

    Bangkok, Thailand

  • Research Site

    Banphaeo, Thailand

  • Research Site

    Chiang Mai, Thailand

  • Research Site

    Phutthamonthon, Thailand

  • Research Site

    Ratchathewi, Thailand

  • Research Site

    Hà Nội, Vietnam

  • Research Site

    Haiphong, Vietnam

  • Research Site

    Ho Chi Minh City, Vietnam

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.